Sustained interest in women's health research, particularly for conditions like endometriosis, requires focused efforts to raise awareness and funding. Despite some advancements, major pharmaceutical companies like Bayer have shifted priorities, and the future of research funding remains uncertain under potential political changes. Concerns about state abortion bans may further complicate recruitment for clinical trials, impacting progress in treatment options.
In Q3 2024, biopharma M&A activity remained robust, highlighted by Lilly's $3.2B acquisition of Morphic and Organon's entry into immune-dermatology with Dermavant. The XBI index gained 7% for the quarter, while follow-on activity slowed, yet capital raised reached $6.7 billion across 24 offerings. Despite a favorable macro environment, large biopharma companies are cautious about mega deals due to impending patent expiries and regulatory uncertainties.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
